The Beneficial Effects of Alpha Lipoic Acid Supplementation on Lp-PLA2 Mass and Its Distribution between HDL and apoB-Containing Lipoproteins in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial
Table 3
BMI and biochemical parameters of participants at the baseline and after 8 weeks of intervention.
Variables
Before
After
BMI (kg/m2)
ALA group
25.41 (1.25)
25.32 (1.27)
0.13
0.16
Placebo group
24.93 (1.26)
2ox4.99 (1.15)
0.52
APO A1 (mg/dl)
ALA group
123.56 (18.99)
128.34 (19.42)
0.06
0.09
Placebo group
126.17 (22.13)
123.00 (22.62)
0.42
Ox-LDL (ng/l)
ALA group
42.82 (1.44)
32.14 (1.46)
0.00
0.00
Placebo group
35.89 (1.61)
34.43 (1.71)
0.19
TC (mg/dl)
ALA group
159.91 (24.22)
151.74 (21.92)
0.15
0.30
Placebo group
153.63 (21.00)
151.69 (17.80)
0.43
HDL (mg/dl)
ALA group
47.43 (5.87)
45.74 (7.64)
0.25
0.98
Placebo group
45.37 (4.88)
43.71 (6.87)
0.26
LDL (mg/dl)
ALA group
78.18 (22.74)
76.01 (23.37)
0.66
0.72
Placebo group
71.94 (18.70)
71.66 (13.38)
0.89
TG (mg/dl)
ALA group
171.26 (31.86)
149.03 (39.23)
0.00
0.03
Placebo group
181.14 (50.42)
180.11 (52.18)
0.89
FBS (mg/dl)
ALA group
134.03 (11.56)
127.74 (15.26)
0.07
0.06
Placebo group
131.51 (14.92)
133.51 (11.71)
0.48
Insulin (mU/l)
ALA group
10.83 (1.53)
10.74 (1.55)
0.54
0.38
Placebo group
10.94 (1.63)
11.12 (1.14)
0.51
HOMA-IR
ALA group
3.58 (0.58)
3.38 (0.62)
0.07
0.058
Placebo group
3.55 (0.66)
3.67 (0.53)
0.34
The results are described as mean (SD). BMI: body mass index; Apo A1: apolipoprotein A1; ox-LDL: oxidized low-density lipoprotein; TC: total cholesterol; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; TG: triglyceride; FBS: fasting blood sugar; HOMA-IR: homeostasis model of assessment index. according to paired t-test; time to group interaction according to two-way repeated measure ANOVA.
